825 Industrial Road, Suite 300
Tel: (650) 837-0111
About Vaxcyte, Inc.
Vaxcyte, Inc. (Nasdaq: PCVX) is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent some of the most common and deadly infectious diseases worldwide. Our exclusively licensed cell-free protein synthesis platform and our proprietary know how enable us to design and produce optimized protein carriers and antigens, the critical building blocks of vaccines, in ways that we believe conventional vaccine technologies cannot. Our lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Our pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease.
73 articles about Vaxcyte, Inc.
SutroVax Announces Name Change to Vaxcyte
SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. “We are committed to developing superior vaccines that provide broader protection than what is available c
SutroVax Appoints Andrew Guggenhime as Chief Financial Officer and Chief Business Officer
SutroVax , a biopharmaceutical company dedicated to the development of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the appointment of Andrew Guggenhime as Chief Financial Officer and Chief Business Officer. In this role, Mr. Guggenhime
SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
SutroVax , a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of a $110 million Series D preferred stock financing, co-led by new investors RA Capital Management and Jan
The company’s lead vaccine candidate, SVX-24, is a preclinical, 24-valent pneumococcal conjugate vaccine.
BioSpace Movers and Shakers, Jan. 31
1/31/2020Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers.
SutroVax Announces Executive Appointment
SutroVax, a biopharmaceutical company dedicated to developing best-in-class conjugate vaccines and novel complex antigen-based vaccines designed to prevent serious infectious diseases, today announced the appointment of Jim Wassil, MS, MBA as Chief Operating Officer
SutroVax Receives CARB-X Award for Up to $15 Million to Develop a Universal Vaccine to Prevent Group A Streptococcus Infections
SutroVax, Inc., today announced it has received an award from CARB-X for up to $15 million in non-dilutive funding to develop a universal vaccine to prevent infections caused by Group A Strep bacteria, which include pharyngitis, impetigo, and necrotizing fasciitis.
SutroVax Announces $85M Series C Financing led by TPG Growth
Provides growth capital to advance pneumococcal vaccine to clinic and beyond
SutroVax Appoints Veteran Vaccine Experts To Executive Team
Dr. Moncef Slaoui, Former GlaxoSmithKline Chairman Of Vaccines, Appointed To SutroVax Board Of Directors
Bay Area's SutroVax Scores $64 Million To Tackle Pneumococcal Vaccines
Sutrovax Announces Appointment Of Industry Leaders To Executive Team, Board & SAB
Sutrovax Announces Appointment Of Paul Sauer As Vice President, Process Development & Manufacturing